



March 23, 2026

Senator Liz Krueger, Chair  
Senate Finance Committee  
Room 124 CAPA  
Albany, NY 12224

Dear Chair Krueger and Members of the Senate Finance Committee,

At Patients Rising, our mission is simple: patients should be informed, visible, and influential in the decisions that shape their health care. With that in mind, we respectfully urge the committee to oppose S.1913/A.6222, which would expand the 340B Drug Pricing Program in New York without first addressing serious gaps in transparency and accountability.

The 340B program was created by Congress to help safety-net providers stretch limited resources and better serve patients who need support. But today, there are growing concerns about whether the program is truly reaching those patients.

In New York, hospitals participating in 340B have established approximately 1,695 contract pharmacy arrangements. Of those, 178 (about 11%) are located outside the state, including in Texas, Arizona, California, and Hawaii. For some hospitals, as many as one-third of their contract pharmacies operate outside New York.

At the same time, many of the pharmacies intended to serve vulnerable patients are located in more affluent areas. Approximately 64% are in higher-income neighborhoods, while only 12% are in rural communities, even though **rural zip codes make up nearly one-third of the state.**

Patients also face a fundamental lack of transparency. Hospitals purchase medicines at deeply discounted 340B prices, yet insurers and patients are often billed at standard rates. The difference frequently becomes hospital general revenue with no real accountability if it is helping patients or the community in which the hospital resides. Patients are rarely told if their prescription was filled under the 340B program or whether they received any benefit from those discounts.

This lack of visibility makes it difficult—if not impossible—for patients, policymakers, and the public to understand whether the program is working as intended.

Before expanding the program, New York should take steps to ensure it is delivering for patients. That includes requiring hospitals to publicly report how much they save through 340B and how those savings are used, as well as evaluating whether those savings are actually reducing costs for patients.

Without these safeguards, expansion risks reinforcing a system where financial benefits are captured by hospitals, pharmacy benefit managers, and large pharmacy chains, while patients see little to no direct relief.

For these reasons, we respectfully urge the Senate Finance Committee to oppose S.1913/A.6222. We encourage the Legislature to instead prioritize reforms that strengthen transparency and ensure the 340B program delivers on its promise to the patients it was designed to serve.

Thank you for your consideration and for your continued work on behalf of New Yorkers.

A handwritten signature in black ink that reads "Terry Wilcox". The signature is written in a cursive, flowing style.

Terry Wilcox  
Co-Founder & Chief Mission Officer  
Patients Rising